Hecolin

BIOLOGICAL2 trials

Sponsors

Norwegian Institute of Public Health, Xiamen Innovax Biotech Co., Ltd

Conditions

Hepatitis E InfectionHepatitis E Virus InfectionHuman Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18

Phase 4

Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.

CompletedNCT02759991

Norwegian Institute of Public HealthHepatitis E Infection

Start: 2017-10-02End: 2019-09-30Updated: 2024-08-15

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Xiamen Innovax Biotech Co., LtdHepatitis E Virus Infection, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18

Start: 2021-10-25End: 2023-06-10Target: 480Updated: 2022-06-13

Related Papers

Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial.

2024-08-0114 citations

Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial.

2024-08-0112 citations

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial.

2023-01-0221 citations

HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh

BMJ Open2020-01-0158 citations